Dysproteinemia and the kidney

Advances in Anatomic Pathology

Volumn 11, Issue 1, 2004, Pages 49-63

  Markowitz, Glen S ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Amyloidosis; Dysproteinemia; Kidney; Monoclonal immunoglobulin deposition disease; Myeloma cast nephropathy

Indexed keywords

IMMUNOGLOBULIN;

HUMAN; HYPOPROTEINEMIA; KIDNEY; KIDNEY DISEASE; PATHOLOGY; PHYSIOLOGY; REVIEW;

HUMANS; HYPOPROTEINEMIA; IMMUNOGLOBULINS; KIDNEY; KIDNEY DISEASES;

EID: 3142782396     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200401000-00005     Document Type: Review

References (48)

1. Roitt I, Brostoff J, Male D. Immunology, 5th ed. London: Mosby, 1998.
2. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol. 2001;12:1482-1492. (Pubitemid 32666331)
3. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845-1851.
4. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc. 1975;50:29-40.
5. Rayner HC, Haynes AP, Thompson JR, et al. Perspectives in multiple myeloma: Survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q J Med. 1991;79:517-525.
6. Kapadia SB. Multiple myeloma: A clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore). 1980;59:380-392. (Pubitemid 10044734)
7. Ivanyi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med. 1990;114:986-987. (Pubitemid 20265301)
8. Paueksakon P, Revelo MP, Horn RG, et al. Monoclonal gammopathy: Significance and possible causality in renal disease. Am J Kidney Dis. 2003;42:87-95. (Pubitemid 36807657)
9. Bartels ED, Brun GC, Gammeltoft A, et al. Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Med Scand. 1954;50:297-302.
10. Defronzo RA, Humphrey RL, Wright JR, et al. Acute renal failure in multiple myeloma. Medicine (Baltimore). 1975;54:209-223.
11. Cohen DJ, Sherman WH, Osserman EF, et al. Acute renal failure in patients with multiple myeloma. Am J Med. 1984;76:247-256. (Pubitemid 14157839)
12. Irish AB, Winearls CG, Littlewood T. Presentation and survival of patients with severe renal failure and myeloma. Q J Med. 1997;90:773-780. (Pubitemid 28008950)
13. Pirani CL, Silva F, D'Agati V, et al. Renal lesions in plasma cell dyscrasias: Ultrastructural observations. Am J Kidney Dis. 1987;10:208-221.
14. Sanders PW, Booker BB, Bishop JB, et al. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990;85:570-576. (Pubitemid 20070067)
15. Huang ZQ, Sanders PW. Biochemical interactions between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest. 1995;73:810-817. (Pubitemid 26002340)
16. Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest. 1997;99:732-736. (Pubitemid 27097676)
17. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001;158:1859-1866. (Pubitemid 32422951)
18. Zucchelli P, Pasquali S, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33:1175-1180.
19. Messiaen T, Deret S, Mougenot B, et al. Adult Fanconi syndrome secondary to light chain gammopathy. Medicine (Baltimore). 2000;79:135-154.
20. Markowitz GS, Flis RS, Kambham N, et al. Fanconi syndrome with free kappa light chains in the urine. Am J Kidney Dis. 2000;35:777-781. (Pubitemid 30185529)
21. Aucouturier P, Bauwens M, Khamlichi AA, et al. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi syndrome. J Immunol. 1993;150:3561-3568. (Pubitemid 23129737)
22. Leboulleux M, Lelongt B, Mougenot B, et al. Protease resistance and binding of Ig light chains in myeloma-associated nephropathies. Kidney Int. 1995;48:72-79.
23. Maldonado JE, Velosa JA, Kyle RA, et al. Fanconi syndrome in adults: A manifestation of a latent form of myeloma. Am J Med. 1975;58:354-364.
24. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59. (Pubitemid 24370135)
25. Bellotti V, Merlini G, Bucciarelli E, et al. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol. 1990;74:65-69. (Pubitemid 20043574)
26. Solomon A, Frangione B, Franklin EC. Bence jones proteins and light chain immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest. 1982;70:453-460. (Pubitemid 12042646)
27. Ozaki S, Abe M, Wolfenbarger D, et al. Preferential expression of λ-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia. Clin Immunol Immunopathol. 1994;71:183-189. (Pubitemid 24147235)
28. Hurle MR, Helms LR, Li L, et al. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA. 1994;91:5446-5460.
29. Nasr SH, Lobritto SJ, Lauring BP, et al. A rare complication of monoclonal gammopathy. Am J Kidney Dis. 2002;40:867-871.
30. Dember LM, Sanchorawala V, Seldin DC, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med. 2001;134:746-753. (Pubitemid 32402067)
31. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637-642. (Pubitemid 33014596)
32. Lin J, Markowitz GS, Nicolaides M, et al. A 76-year-old woman with nephrotic syndrome. Am J Kidney Dis. 2001;38:437-440.
33. Kambham N, Markowitz GS, Appel GB, et al. Heavy chain deposition disease: The disease spectrum. Am J Kidney Dis. 1999;33:954-962. (Pubitemid 29214696)
34. Heilman RL, Velosa JA, Holley KE, et al. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis. 1992;20:34-41.
35. Ronco LM, Alyanakian MA, Mougenot B, et al. Light chain deposition disease: A model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol. 2001;12:1558-1565. (Pubitemid 32666341)
36. Randall RE, Williamson WC, Mullinax F, et al. Manifestations of systemic light chain deposition. Am J Med. 1976;60:293-299.
37. IV subgroup in light chain deposition disease. Immunol Lett. 1994;42:63-66.
38. Zhu L, Herrera GA, Murphy-Ullrich JE, et al. Pathogenesis of glomerulosclerosis in light chain deposition disease: Role for transforming growth factor-β. Am J Pathol. 1995;147:375-385.
39. Hendershot L, Bole D, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol. 1987;104:761-767. (Pubitemid 17024730)
40. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. Am J Med. 1974;57:775-787.
41. Morel-Maroger L, Basch A, Danon F, et al. Pathology of the kidney in Waldenstrom's macroglobulinemia. N Engl J Med. 1970;283:123-129.
42. Rosenstock JL, Markowitz GS, Valeri AM, et al. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int. 2003;63:1450-1461. (Pubitemid 36350010)
43. Alpers CE. Immunotactoid (microtubular) glomerulopathy: An entity distinct from fibrillary glomerulonephritis? Am J Kidney Dis. 1992;19:185-191.
44. Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: A distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. (in press).
45. Alpers CE, Tu WH, Hopper J Jr, et al. Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol. 1985;16:294-304. (Pubitemid 15143679)
46. Ronco PM. Paraneoplastic glomerulopathies: New insights into an old entity. Kidney Int. 1999;56:355-377. (Pubitemid 29300560)
47. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164-1172. (Pubitemid 32472629)
48. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64:281-289. (Pubitemid 36714182)